Cel
THALAMOSS is aimed at development of universal sets of markers and techniques for stratification of β-thalassaemia patients into treatment subgroups for (a) onset and frequency of blood transfusions, (b) choice of iron chelation, (c) induction of fetal hemoglobin, (d) prospective efficacy of gene-therapy. At present, no framework exists to guide therapeutic decisions and personalised treatment of β-thalassaemia.
THALAMOSS Workpackages: WP1. Recruitment, patient characterization and development of erythroid precursor cells cultures; WP2. Omics analyses; WP3. Novel therapeutic approaches; WP4. Data analysis; WP5. Dissemination and exploitation; WP6. Regulatory and ethical issues; WP7. Management.
The impact of THALAMOSS is the provision of novel biomarkers for distinct treatment subgroups in β-thalassaemia (500-1000 samples from four European medical centres), identified by combined genomics, proteomics, transcriptomics and tissue culture assays, and establishment of routine techniques for detection of these markers. Translation of these activities into the product portfolio and R&D methodology of participating SMEs will be a major issue. THALAMOSS tools and technologies will (a) facilitate identification of novel diagnostic tests, drugs and treatments specific to patient subgroups and (b) guide conventional and novel therapeutical approaches for β-thalassaemia, including personalised medical treatments.
Key researchers of THALAMOSS are R.Gambari (Ferrara University, Italy), M. Kleanthous (The Cyprus Foundation for Muscular Dystrophy Research, Cyprus), S.Philipsen (Erasmus Universitair Medisch Centrum Rotterdam, The Netherlands), E.Katsantoni (Biomedical Research Foundation, Academy of Athens, Greece), S.Rivella (Cornell University, NY, USA - The Children's Hospital of Philadelphia, Philadelphia, USA), P.Holub (Masaryk University, Czech Republic), P. Moi (Cagliari University, Italy), S. Menzel and SL.Thein (King’s College Hospital, UK), E.Voskaridou (Laiko General Hospital, Greece). Participating SMEs are Biocep (Israel), NovaMechanics Ltd. (Cyprus) and IRBM (Italy). Industrial activities are also provided by Harbour Antibodies (The Netherlands).
Dziedzina nauki
- natural sciencescomputer and information sciencesdata science
- natural sciencesbiological sciencesgenetics
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsproteomics
- medical and health sciencesbasic medicineneurologymuscular dystrophies
- social sciencespolitical sciencesgovernment systems
Zaproszenie do składania wniosków
FP7-HEALTH-2012-INNOVATION-1
Zobacz inne projekty w ramach tego zaproszenia
System finansowania
CP-FP - Small or medium-scale focused research projectKoordynator
44121 Ferrara
Włochy
Zobacz na mapie
Uczestnicy (13)
2371 AGIOS DOMETIOS
Zobacz na mapie
3015 GD Rotterdam
Zobacz na mapie
115 27 Athina
Zobacz na mapie
14850 Ithaca Ny
Zobacz na mapie
601 77 Brno
Zobacz na mapie
09124 Cagliari
Zobacz na mapie
WC2R 2LS London
Zobacz na mapie
11527 Athina
Zobacz na mapie
1070 Nicosia
Zobacz na mapie
1311001 TZFAT
Zobacz na mapie
3013 AK Rotterdam
Zobacz na mapie
00040 Pomezia Rm
Zobacz na mapie
19104 Philadelphia
Zobacz na mapie